FORM 6 - K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
The Securities Exchange Act of 1934
For the month of August 2000
Commission File Number 0-29350
VASOGEN INC.
(Translation of Registrant's name into English)
2155 Dunwin Drive, Suite 10, Mississauga, Ontario, L5L 4M1
(Address of principal executive offices)
(Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20 - F or Form 40 - F.)
Form 20 - F X Form 40 - F
----- -----
(Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.)
Yes No X
------ ------
<PAGE>
This Form 6-K consists of:
A press release issued by Vasogen Inc. on August 14, 2000, entitled: "Vasogen to
Conduct Quarterly Conference Call".
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
VASOGEN INC.
By ____________________________
(Name: Christopher Waddick)
(Title: Vice-President, Finance & CFO)
Date: August 15, 2000
<PAGE>
Vasogen Inc.
INVESTOR CONTACT
2155 Dunwin Drive
Mississauga, ON, Canada L5L 4M1 Glenn Neumann
tel: (905) 569-2265 fax: (905) 569-9231 Investor Relations
www.vasogen.com (905) 569-9065
[email protected]
--------------------------------------------------------------------------------
FOR IMMEDIATE RELEASE
Vasogen to Conduct Quarterly Conference Call
Toronto, Ontario, (August 14, 2000) -- Vasogen Inc. (TSE:VAS; AMEX:MEW) will
conduct a conference call on Tuesday, August 15, 2000 at 4:10 p.m. Eastern Time
to provide a quarterly update. Interested parties are invited to attend by
connecting 10 minutes prior to the call to one of the following:
--------------------------------- -------------------------
Direct Dial 416-231-6596
--------------------------------- -------------------------
Toll-free 1-800-361-1028
--------------------------------- -------------------------
Audio Web Cast* www.vasogen.com
--------------------------------- -------------------------
*RealPlayer required
The conference call will be available for re-broadcast through August 18th and
may be accessed by calling:
------------------- ------------------------ -----------------
Direct Dial 416-640-1917 Passcode: 56377#
------------------- ------------------------ -----------------
Toll-free 1-877-289-8525 Passcode: 56377#
------------------- ------------------------ -----------------
The audio web cast will also be available on Vasogen's website at
www.vasogen.com.
Vasogen is focused on developing immune modulation therapies to advance the
treatment of cardiovascular, autoimmune and related inflammatory diseases. These
therapies are designed to target fundamental disease-causing events, providing
safe, effective treatment.
Statements contained in this press release, including those pertaining to
scientific and clinical research, commercialization plans, strategic alliances,
and intellectual property protection, other than statements of historical fact,
are forward-looking statements subject to a number of uncertainties that could
cause actual results to differ materially from statements made.
